CLINICAL TRIALS PROFILE FOR NAVITOCLAX
✉ Email this page to a colleague
Clinical Trials for Navitoclax
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT00481091 ↗ | A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia | Active, not recruiting | Genentech, Inc. | Phase 1/Phase 2 | The Phase 1 portion of the study will evaluate the pharmacokinetic profile and safety of ABT-263 under two different dosing schedules with the objective of defining the dose limiting toxicity and maximum tolerated dose. The Phase 2a portion of the study will evaluate ABT-263 at the defined recommended Phase 2 dose to obtain additional safety information and a preliminary assessment of efficacy. The Extension Study portion will allow active subjects to continue to receive ABT-263 for up to 11 years after the last subject transitions with less frequent study evaluations. |
| NCT00481091 ↗ | A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia | Active, not recruiting | AbbVie | Phase 1/Phase 2 | The Phase 1 portion of the study will evaluate the pharmacokinetic profile and safety of ABT-263 under two different dosing schedules with the objective of defining the dose limiting toxicity and maximum tolerated dose. The Phase 2a portion of the study will evaluate ABT-263 at the defined recommended Phase 2 dose to obtain additional safety information and a preliminary assessment of efficacy. The Extension Study portion will allow active subjects to continue to receive ABT-263 for up to 11 years after the last subject transitions with less frequent study evaluations. |
| NCT00481091 ↗ | A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia | Active, not recruiting | AbbVie (prior sponsor, Abbott) | Phase 1/Phase 2 | The Phase 1 portion of the study will evaluate the pharmacokinetic profile and safety of ABT-263 under two different dosing schedules with the objective of defining the dose limiting toxicity and maximum tolerated dose. The Phase 2a portion of the study will evaluate ABT-263 at the defined recommended Phase 2 dose to obtain additional safety information and a preliminary assessment of efficacy. The Extension Study portion will allow active subjects to continue to receive ABT-263 for up to 11 years after the last subject transitions with less frequent study evaluations. |
| NCT00788684 ↗ | Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers | Active, not recruiting | Genentech, Inc. | Phase 1 | This is a Phase 1 study evaluating the safety of ABT-263 administered in combination with rituximab in subjects with CD20-positive lymphoproliferative disorders. The extension portion of the study will allow active subjects to continue to receive ABT-263 for up to 9 years after the last subject transitions with quarterly study evaluations. |
| NCT00788684 ↗ | Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers | Active, not recruiting | AbbVie (prior sponsor, Abbott) | Phase 1 | This is a Phase 1 study evaluating the safety of ABT-263 administered in combination with rituximab in subjects with CD20-positive lymphoproliferative disorders. The extension portion of the study will allow active subjects to continue to receive ABT-263 for up to 9 years after the last subject transitions with quarterly study evaluations. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Navitoclax
Condition Name
Clinical Trial Locations for Navitoclax
Trials by Country
Clinical Trial Progress for Navitoclax
Clinical Trial Phase
Clinical Trial Sponsors for Navitoclax
Sponsor Name
